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Abstract 
In this edition of the Huntington’s Disease Clinical Trials Corner we expand on the 
GENERATION-HD1 and on the PACE-HD trials, and we list all currently registered 
and ongoing clinical trials in Huntington’s disease.  
Main text 
INTRODUCTION 
The Huntington’s Disease Clinical Trials Corner is a regular section devoted to 
highlighting ongoing and recently completed clinical trials in Huntington’s disease 
(HD). Clinical trials previously reviewed by the Huntington’s Disease Clinical Trials 




In this edition, we highlight the GENERATION-HD1 trial (NCT03761849)(1), and the 
PACE-HD trial (NCT03344601)(2), and briefly summarise the trial evidence around 
physiotherapy and exercise interventions in HD. Finally, we tabulate all currently 
registered and ongoing clinical trials in tables 2 to 4. For further details on the 
methodology used, please refer to the first edition of Huntington’s Disease Clinical 
Trials Corner(3). 
If you would like to draw attention to specific trials, please feel free to email us at: 
f.rodrigues@ucl.ac.uk and e.wild@ucl.ac.uk. 
 
In addition to the above, the published report of the PRIDE-HD trial (NCT02006472) 
is worthy of mention. The paper reports that “the study did not meet its primary of 
secondary endpoints at 26 weeks”(4), confirming the results of previous trials(5-7) 
and suggests that pridopidine is unlikely have an effect on the motor symptoms of 
HD as assessed with the Unified Huntington’s Disease Rating Scale (UHDRS) Total 
Motor Score (TMS).   
ONGOING CLINICAL TRIALS 
A list of all ongoing clinical trials is given in Tables 2, 3 and 4. 
 
GENERATION-HD1 (NCT03761849) 
Study title: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III 
Clinical Study to Evaluate the Efficacy and Safety of Intrathecally Administered 
RO7234292 (RG6042) in Patients With Manifest Huntington's Disease(1). 
Intervention: RG6042 (120mg) – formerly known as IONIS-HTTRx / ISIS443139 – an 
antisense oligonucleotide that targets the HTT transcript allele-nonspecifically with 
the aim of lowering the production of mutant huntingtin protein (8). 
Description: The GENERATION-HD1 trial, sponsored by Hoffmann-La Roche, aims 
to evaluate the efficacy, safety, and biomarker effects of monthly and bimonthly (i.e. 
every other month) 120mg of intrathecal RG6042 in adults (25 to 65 years of age) 
with manifest HD (i.e. a UHDRS Diagnostic Confidence Level of 4, a UHDRS 
Independence Score [IS] above or equal to 70, and a CAG-age Product equal or 
greater than 400) and intact functional independence at baseline to maintain self-
care and core activities of daily living, comparing with intrathecal placebo, for 
disease modification. 
This trial is a phase 3, international, multi-centre, randomized, placebo controlled, 
double-blind, parallel study. It will have 3 study arms: monthly intrathecal injections 
of 120mg RG6042; monthly intrathecal injections alternating between 120mg 
RG6042 and placebo; and monthly intrathecal placebo. The intervention will be 
administered for 25 months, and participants will be followed for 29 months. All 
participants are expected to be invited to an optional open-label extension (OLE) 
involving monthly or bimonthly drug administration after the end of the blinded phase 
of the study, assuming the program is continuing.  
The trial had not started recruitment at the time of writing, but has a recruitment 
target of 660 participants, over around 15 countries and 80 to 90 study sites, and it is 
planned to start enrolment by early 2019. It is currently public that recruitment will 
happen in the United States of America and Canada, where expected clinical sites 
were announced in December(9). Details about further countries and sites will be 
released in the future. 
This pivotal trial will have two primary clinical outcomes for regulatory purposes, the 
UHDRS Total Functional Capacity (TFC) for the FDA, and the composite UHDRS 
(cUHDRS)(10) for the EMA(11). Secondary outcomes will involve other components 
of the UHDRS, clinical global impression, adverse events, the Montreal Cognitive 
Assessment (MoCA), the Columbia-Suicide Severity Rating Scale (C-SSRS), 
pharmacokinetic markers, cerebrospinal fluid mutant huntingtin and neurofilament 
light chain, and MRI brain volumes. 
Sponsors/funders: Hoffmann-La Roche 
Comments:  
This trial is the first to test huntingtin-lowering in a pivotal phase 3 trial, and is part of 
a development plan that includes the completed first-in-man phase 1b/2a IONIS-
HTTRX (NCT02519036) trial(12), its ongoing OLE (NCT03342053)(13), the now-
recruiting HD Natural History Study (NCT03664804)(14), and the imminent 
GENERATION-HD1 (NCT03761849) trial(1). The phase 1b/2a involved 46 people 
with early stage HD and showed RG6042 to be safe and well-tolerated, and to 
reduce cerebrospinal fluid mutant huntingtin concentrations in a dose-dependent 
manner (15). Results are currently being prepared for peer-reviewed publication(11). 
After completion, all participants were invited to an OLE study aimed at studying 
long-term safety, tolerability, pharmacokinetics and pharmacodynamics of RG6042 
over 15 months; this is currently ongoing. Participants entering the OLE were 
randomly allocated to monthly or 2-monthly intra-thecal doses of 120mg RG6042. 
The HD Natural History Study is a prospective longitudinal observational study that 
aims to recruit 100 people with early stage HD, matched individually to the 
participants of the open label extension study(16). It aims to measure clinical and 
biomarkers (i.e. cerebrospinal fluid neurofilament light chain, mutant huntingtin and 
tau, brain MRI volumes, and digital biomarkers) over a 15-month period in a sample 
comparable to the phase 1b/2a and open label extension studies. Participants are 
being recruited in United States of America, Canada, Germany and United Kingdom. 
Participants will be offered continued open-label access to RG6042 after study 
termination. 
Notably, for the pivotal phase 3 trial, PRECISION-HD1, Roche has opted for an 
enrichment strategy based on the inclusion criteria “CAG-age Product superior to 
400”. The CAG-age product (CAP score) is an estimate of lifetime exposure to 
mHTT toxicity (17), given by: 
[HTT CAG repeat length – 33.66]  age 
 
 
Together with the remaining inclusion criterial, namely the UHDRS Diagnostic 
Confidence Level of 4, a UHDRS IS above or equal to 70, and functional 
independency at baseline, the use of a CAP score cutoff aims to produce a relatively 
homogeneous sample of early stage participants, whose expected progression 
during trial follow-up is greater and less variable (17). This should improve the 
statistical power of the sample. It produces rigid minimum age cutoffs for each HTT 
CAG repeat length, as shown in table 5. This criterion will doubtless be a point of 





Study title: A Longitudinal Cohort Study With Nested Randomised Pragmatic 
Controlled Trial to Evaluate Physical Activity and Exercise Related Outcomes in 
People With Huntington's Disease (PACE-HD)(2). 
Intervention: Supported structured aerobic exercise training program (18 face-to-face 
coaching sessions of ~1 hour). 
Description: The PACE-HD trial, sponsored by Cardiff University and CHDI 
Foundation, Inc., aims to evaluate the feasibility, tolerability, and safety of supported 
structured aerobic exercise training program in adults (≥18 years of age) with 
genetically confirmed early manifest HD, compared with activity as usual. 
PACE-HD is an international, multi-centre, observation study with a nested 
randomized, controlled, open label, parallel study. It will involve 120 participants, 60 
of whom will take part on a longitudinal observational evaluation of physical fitness 
and physical activity over a period of 12 months, while the remaining 60 will be 
randomized to a supported structured aerobic exercise training program, or exercise 
as usual over a period of 12 months. Recruitment is currently open at various sites in 
the United States of America, Germany, and Spain.  
The primary outcomes are data completeness, recruitment, retention, safety, 
adherence, fidelity, and acceptability. Secondary outcomes include exercise tests, 
walk endurance measures, the HD Pro-Triad, the Brunel Lifestyle Physical Activity 
Questionnaire, and digital biomarkers. 
Sponsors/funders: Cardiff University and CHDI Foundation, Inc. 
Comments:  
With multiple trials of agents intended to engage with the core pathobiology of HD 
underway, and more planned, the relevance of clinical interventions such as 
rehabilitation therapies, as both stand-alone and adjunctive therapies, has never 
been more significant.  Similar to current management guidelines for Parkinson’s 
disease(18) and multiple sclerosis(19), rehabilitation therapies - including 
physiotherapy, occupation therapy, exercise and physical activity - could be used 
alongside disease-modifying interventions with the potential to maximize patient 
outcomes. 
Animal models of HD have provided pre-clinical evidence that exercise has the 
potential to modify disease progression. In R6/1 mice, sustained wheel running was 
shown to improve gait and motor coordination, as well as reduce striatal neuron 
loss(20).  More recent work with the longer life-span CAG140 mouse model 
demonstrated that 6 months of treadmill training resulted in increased striatal 
dopamine D2 receptor expression and dopamine neurotransmitter levels, reduction 
in HTT aggregate formation, as well as improved behavioural and cognitive 
symptoms(21). These pre-clinical findings have set the stage for several clinical 
feasibility studies in people with early and moderate HD(22-25), as well as in several 
multi-disciplinary rehabilitation trials(26-30).  
Combined pre-clinical and clinical data provide support for the evaluation of exercise 
as a therapeutic intervention strategy in HD. A recent systematic review reported on 
findings from 20 studies and found preliminary support for the beneﬁts of exercise 
and physical activity in terms of motor function, gait speed, and balance(31, 32). The 
review also reported a range of physical and social beneﬁts identiﬁed through 
patient-reported outcomes. Interventions incorporating aerobic and strengthening 
exercises were most prevalent across studies, and several studies noted 
improvement or maintenance of motor function over 9 months or longer. 
In order for rehabilitation interventions to be considered an important adjunctive 
therapy alongside pharmacological interventions, high-quality studies using 
innovative statistical methods and trials designs are needed. PACE-HD is a 
pragmatic study that includes both a longitudinal observational study and a nested 
(i.e. within-cohort) randomized controlled trial of a 12-month physical therapy and 
exercise intervention. The intervention incorporates the use of wearable physical 
activity monitors to measure both outcomes and activity levels throughout the trial. 
The study is conducted alongside Enroll-HD, which minimizes subject burden and 
will provide a basis for comparative analysis on disease progression measures. 
Results of this study are due in the summer of 2020. 
A formal Clinical Guideline for Exercise in HD is currently in development. This will 
provide evidence-based recommendations for healthcare providers and persons with 
HD, and is planned to be available later in 2019. 
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Table 1 – Clinical trials previously reviewed by the Huntington’s Disease Clinical Trials Corner. *IONIS-HTTRx, ISIS 443139 and 
RG6042 refer to the same molecule. 
  Trial name Intervention Edition 
NCT02519036 IONIS-HTTRx IONIS-HTTRx* 
September 2017(3) 
NCT02215616 LEGATO-HD Laquinimod 
NCT02197130 Amaryllis PF-02545920 
NCT02006472 PRIDE-HD Pridopidine 
NCT03225833 PRECISION-HD1 WVE-120101 
February 2018(33) NCT03225846 PRECISION-HD2 WVE-120102 
NCT01795859 FIRST-HD Deutetrabenazine 
NCT02481674 SIGNAL VX15/2503 
August 2018(34) 
NCT00712426 CREST-E Creatine 
NCT03761849 GENERATION-HD1 RG6042* 
January 2018 
NCT03344601  PACE-HD Physical activity 
 
Table 2 
Table 2 – Ongoing pharmacological clinical trials registered at the World Health Organization (WHO) International Clinical Trials 
Research Platform (ICTRP) for people with Huntington’s disease (HD). N/S, not specified; PD, Parkinson’s disease; VMAT2, 
Vesicular Monoamine Transporter 2. Note: IONIS-HTTRx, ISIS 443139 and RG6042 refer to the same molecule. New trials since 
the last Clinical Trials Corner are indicated by *. 
Registration ID Trial name Intervention 
Mechanism of Action 






















NCT03787758* - SAGE-718 
NMDA positive 
allosteric modulator 












NCT03575676* - SOM3355 
VMAT2 inhibitor and 
β1 antagonist 
Early and 
moderate HD with 
chorea 






30 SOM Biotech SL 
Spain  
(multi centre) 
NCT03515213* - Fenofibrate PPARα agonist HD Placebo 
Pharmacodynamics 































































































NCT02453061 TRIHEP 3 Triheptanoin Anaplerotic therapy HD Placebo 
Pharmacodynamic 








de la Santé Et 











Tetrabenazine VMAT2 inhibitor HD with impulsivity None 
Cognitive and 
behavioural effects 















moderate HD with 
irritability 
Placebo 









































NCT02336633 REVHD Resveratrol Dietary supplement HD Placebo 
Neuroimaging 

























































Nicotinic acid receptor 
partial agonist 
HD Placebo 















Table 3 – Ongoing invasive non-pharmacological clinical trials registered at the World Health Organization (WHO) International 
Clinical Trials Research Platform (ICTRP) for people with Huntington’s disease (HD). AD, Alzheimer’s disease, CBD; Corticobasal 
Degeneration; DBS, deep brain stimulation; ET, Essential Tremor; GP, Globus pallidus; HT, Holmes Tremor; MNC, mononuclear 
cells; MS, Multiple Sclerosis; PD, Parkinson’s disease; TD, Tardive dyskinesia; WD, Wilson’s disease. New trials since the last 
Clinical Trials Corner are indicated by *. 
Registration ID Trial name Intervention 
Mechanism 
of Action 
























NCT02728115* SAVE-DH Cellavita 
Stem cell 
therapy 






6 Azidus Brasil 
Brazil 
(single centre) 





















HD, AD, PD, 
CBD, MS 
















































































































Table 4– Ongoing non-invasive non-pharmacological clinical trials registered at the World Health Organization (WHO) International 
Clinical Trials Research Platform (ICTRP) for people with Huntington’s disease (HD). AD, Alzheimer’s disease; ALS, Amyotrophic 
Lateral Sclerosis; ET, Essential Tremor; HT, Holmes Tremor; MS, Multiple Sclerosis; PD, Parkinson’s disease; TD, Tardive 
dyskinesia. New trials since the last Clinical Trials Corner are indicated by *. 
Registration ID Trial name Intervention 
Mechanism of 
Action 







































































HD and PD 
Sham 
stimulation 




































































HD and ALS None 
Swallowing 
function and 





































effect at 2 
weeks, 3 months 












































Table 5. Minimum age at which individuals with each HTT CAG count will have a 
CAP score of ≥400, permitting them to meet this inclusion criterion for Generation-
HD1 and related trials. Note that those with CAG counts of 36-39 will never meet this 
criterion while they still meet the maximum age inclusion criterion of 65, while those 
with repeats of 50 or over all meet the CAP score cutoff, but would need to 
additionally meet the minimum age inclusion criterion of 25. 















50 or over 25 
 
 
